To determine whether oxidative modification of apoA-I tyrosine residues was responsible for the MPO-mediated inactivation of cholesterol acceptor activity, we made recombinant apoAI with site-specific substitutions of all seven tyrosine residues to phenylalanine. ApoAI and the tyrosine-free apoAI were equally susceptible to dosedependent MPO-mediated loss of ABCA1-dependent cholesterol acceptor activity, as well as lipid binding activity. MPO modification altered the migration of apoAI on SDS gels and decreased its ␣-helix content. MPO-induced modification also targeted apoAI tryptophan and lysine residues. Specifically, we detected apoAI tryptophan oxidation to mono-and dihydroxytryptophan and apoAI lysine modification to chlorolysine and 2-aminoadipic acid. Thus, tyrosine modification of apoAI is not required for its MPO-mediated inhibition of cholesterol acceptor activity.The levels of high density lipoprotein (HDL) 2 and its major protein component, apolipoprotein AI (apoAI), are inversely correlated to the risk of coronary artery disease in developed countries (1). Their protective effects may be mediated by several activities, including their ability to remove excess cholesterol from peripheral tissues for delivery to the liver via the reverse cholesterol transport pathway. Cellular lipid efflux to apoAI, as well as HDL biogenesis, is mediated by the transporter ABCA1, which is defective in Tangier disease (2-5). Although apoAI may have additional anti-atherogenic properties, recent studies in the mouse have proved that apoAI can stimulate the removal of the preloaded cholesterol from macrophages and the appearance of this cholesterol in the feces (6). ApoAI is a 243-residue polypeptide containing an N-terminal domain followed by ten 11-or 22-residue amphipathic ␣-helical domains (7). ApoAI adopts two distinct physiological conformations, lipid-free and lipid-bound. In the absence of lipid, apoAI is thought to exist as a helical bundle or hairpin that is stabilized by hydrophobic helix-helix interactions (8 -12). These helical bundles undergo a conformational change during lipid association that results in the substitution of helix-helix interactions for helix-lipid interactions (13).Myeloperoxidase (MPO) is a neutrophil and monocyte/macrophage enzyme that utilizes hydrogen peroxide and chloride to generate the chlorinating oxidant HOCl to kill pathogens (14). MPO can also utilize hydrogen peroxide and nitrite to generate nitrating oxidants capable of initiating lipid peroxidation and protein nitration (15). MPO can promote both protein nitration and lipid peroxidation in vivo (16 -18), and the blood levels of MPO and nitrotyrosine are predictors of an increased risk of cardiovascular disease (19 -21). We recently described that plasma and atherosclerotic lesion-derived apoAI are selective targets for MPO modification resulting in the appearance of specific nitro-and chlorotyrosine residues, and that this modification dose-dependently decreased the cholesterol acceptor and lipid binding activities of apoAI...